Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agree
Hard to believe that they want to defend their governance on the public stage when the stock has been dog paddling around $1. Q3 CC should be interesting - if they don’t show some significant results and positive action in all the markets they’re working on, they should just hand Denner the keys and let him have a turn.
The company should update their website to say "A BOLD VISION...with no urgency!"
Let us know when you’ve mastered Irish history. Better yet, the history of your local pub.
Still day drinking?
Why would Denner waste his time and energy for only $5?
There’s a reason KM was a “consultant” instead of on the fast track to upper management at Merck or poached by some other BP.
He doesn’t post screen shots because he doesn’t know how. Which is pretty amazing for the world’s greatest day trader!
Pretty sure your igloo would melt before the first feeder band blew through!
Something unhealthy about a doctor who cheerleads the failure of a company that sells a lifesaving drug.
Billy Ray Valentine would do a better job.
When was your medical license revoked?
Is the arbitration binding?
Didn't you listen to the man? He said 2023 is going to be the Chinese Year of the Revenue.
Not if you use common core math.
You put a lot of effort into that. Congratulations!
Anyone who has to align themselves with Lilylang from Stocktwits is clearly crying out for attention. I would suggest that you and Ralphie get a hotel room and invite Lily to watch.
Your cage is clean. You can go home now!
Not with Biden in the White House.
I thought there was some requirement for the Vascepa sold in China to be manufactured there?
Hey, Ralphie, I think I speak for all of America when I say your EUNUCHA line got old about five minutes after you first posted it.
Thanks for reading. Now, back to the point at hand. Do you have anything to back your wild statement up or are you just pulling it out of your ass?
It's ok to opine, but to state this as if you actually had a source makes you look not so smart. Or as we like to say in the pool halls, a dumb ass!
That could be a negotiating tactic.
Was Germany the only “big 5” European country where Amarin could sell Vazkepa prior to reimbursement approval?
Bastards!
That’s not a trade confirmation. It’s an order and no confirmation that he went forward and executed.
He’s a lawyer with no biotech background., so…
When you flood the carburetor with the strategic petroleum reserves and tame the masses into not wanting to spend $5 on a gallon of gas, guess what happens? It’s obvious, eh captain?
Nobody really cares.
Denner is a rogue investor?
My advice, any woman who begins her screen name with “PMS”, stay away from!
Might want to order a decaf!
Ten bucks says a successful RESPECT trial won't shut Nissen up.
So why can’t Amarin find the voices to get that message across loud and clear?
They launched Germany on September 13, 2021 and all we’ve heard are excuses. And KM’s expertise, supposedly, is sales and marketing.
Drugmakers Hope New Heart Drugs Boost Sales, Revive Market
Merck, Novartis and others are seeking to revive $48 billion market, which had shrunk after top-selling cholesterol and other drugs lost patent protection
Sales of cholesterol-lowering statins, which helped drive the cardiovascular drug market, plunged when patents ran out and lower-priced generics arrived.
PHOTO: PAUL J. RICHARDS/AFP/GETTY IMAGES
By Jared S. HopkinsFollow
July 26, 2022 9:14 am ET
SAVE
PRINT
TEXT
6
The once lucrative heart-drug market is now poised to make a comeback, but at the cost of heavy investments in research and deal making.
After watching lower-priced generics seize sales of once-highflying blood-pressure, cholesterol and other heart drugs, companies struggled to discover replacements and then win reimbursement for five-figure prices. Drugmakers are now rolling out new medicines, though their commercial prospects are uncertain.
Novartis AG recently launched a new cholesterol-lowering therapy bought in a nearly $10 billion deal, while Bristol-Myers Squibb Co. has begun selling a next-generation heart-disease drug that was the centerpiece of a recent $13 billion acquisition.
Alnylam Pharmaceuticals Inc. and Amgen Inc., meanwhile, are working on drugs that silence the defective genes behind some heart conditions.
“We’re in a new era,” said Steven Nissen, a cardiologist at the Cleveland Clinic. “We have gotten really smart at creating therapies that specifically target what is causing disease.”
Pricing has already been a thorny issue. Next-generation cholesterol treatments called PCSK9 inhibitors, which interfere with a protein that makes it difficult for the body to clear bad cholesterol, haven’t sold well. The drugs require regular infusions, and carry high sticker prices, especially compared with statins such as Lipitor now sold in lower-cost generic versions.
New technologies and better insights into the molecular biology underlying cardiovascular diseases have reinvigorated interest in treatments.
PHOTO: ANTHONY DEVLIN/ZUMA PRESS
Developing other new heart drugs has been relatively slow. The clinical trials testing the experimental drugs involve more subjects and take longer than studies of cancer therapies, for instance. Also, many of the drugs target heart conditions that are more complex than tumors driven by single-gene mutations.
“Cholesterol issues, blood pressure issues, diabetes, diet, physical activity, behavior—all these things work together in the background of your genetic predisposition,” said Donald Lloyd-Jones, a cardiologist and chief of preventive medicine at Northwestern University’s Feinberg School of Medicine in Chicago.
Driving the industry’s reinvigorated interest in cardiovascular treatments, however, are a combination of new technologies and better insights into the molecular biology underlying the diseases. And the industry has already seen the potential sales from a robust heart-drugs market
The new products could add $17 billion to the $48 billion worldwide heart-drugs market by 2026, according to Cowen & Co. A next-generation Merck & Co. hypertension treatment could ring up $4 billion in annual sales, while the new Novartis cholesterol-lowering therapy could generate more than $6 billion a year, analysts estimate.
SHARE YOUR THOUGHTS
How might the availability of new cardiovascular drugs change your life or that of someone you know? Join the conversation below.
“There is a resurgence in successful development and pipeline presence for cardiovascular disease,” said Eliav Barr, R&D chief at Merck, which acquired its therapy for pulmonary arterial hypertension as part of an $11.5 billion deal last year for the biotech Acceleron. The drug, called sotatercept, is in late-stage testing.
Drugs treating high blood pressure, hypertension and high cholesterol had powered the pharmaceutical industry for decades. Pfizer Inc.’s Lipitor and other cholesterol-lowering statins helped push the cardiovascular drug market to nearly $87 billion in 2010, according to Evaluate, a research firm.
Sales plunged as patents protecting the products ran out and lower-priced generics arrived. Drugmakers shifted focus to other, more lucrative areas, including cancer and autoimmune diseases like rheumatoid arthritis.
Advertisement - Scroll to Continue
Yet physicians say many people aren’t well treated by the older drugs and could benefit from new ones. Cardiovascular diseases remain the leading cause of death globally, killing roughly 18 million people annually, according to the World Health Association.
Advances in understanding the role that specific proteins and genes play in diseases provided new drug targets.
Pfizer’s Vyndamax was approved in the U.S. in 2019, the first drug cleared for a rare and fatal heart disease caused by the misfolding and clumping of proteins.
The new Bristol drug Camzyos treats a genetic heart disease by blocking a protein found to play a key role in causing the heart muscle to thicken.
PHOTO: BRISTOL-MYERS SQUIBB CO.
Researchers discovered that the plaques of proteins accumulated in the heart, thickening its muscle and interfering with its ability to function. Vyndamax works by reducing the protein buildup, which is known as transthyretin mediated amyloidosis.
The new Bristol drug, Camzyos, treats a different genetic heart disease by blocking a different protein that was found to play a key role in causing the heart muscle to thicken, restricting the organ’s ability to pump blood.
Academic researchers discovered the roots of that condition, called hypertrophic cardiomyopathy, in genetic mutations to a protein called myosin. Their findings prompted companies including MyoKardia, which Bristol bought to gain the rights to Camzyos, to develop treatments, according to industry officials.
The advent of the gene-silencing drug technology called RNA interference has also contributed to the development of several new heart medicines.
RNA interference, or RNAi, blocks genes from producing proteins found to drive disease.
Alnylam, which helped pioneer the technology, has won regulatory approval in the U.S. to sell RNAi drugs Onpattro and Amvuttra for treatment of the nerve damage caused by protein buildup known as transthyretin-mediated amyloidosis, or TTR. Alnylam is testing the drugs to see if they also work against heart failure caused by the TTR disease.
Research of patients taking the drugs suggests cardiac benefits that could reduce the risk of cardiovascular events, said Pushkal Garg, Alnylam’s chief medical officer. Studies of Onpattro should yield results later this year, and of Amvuttra in 2024.
Leqvio, another RNAi drug, interferes with the production of the PCSK9 protein that makes it difficult for the body to clear the bad form of cholesterol known as LDL or low-density lipoprotein, said Victor Bulto, president of innovative medicine at Novartis. Leqvio was developed by Alnylam, which licensed the rights to The Medicines Company, which Novartis later acquired for $9.7 billion.
The Food and Drug Administration approved Leqvio last December in people who have extremely high cholesterol that statins can’t control.
The FDA in December approved Novartis’s Leqvio to treat extremely high cholesterol that statins can’t control.
PHOTO: NOVARTIS
Manufacturers of older PCSK9-blocking drugs cut prices after health insurers chafed at prices that could surpass $14,000 a year and restricted use, hurting sales.
Novartis said it expects its newer PCSK9 drug Leqvio to perform better than older PCSK9-blocking rivals because patients can take it twice a year, rather than two times a month. Novartis also listed Leqvio for $6,500 a year after the first year, comparable to the lowered prices for its older rivals.
Amgen’s researchers are developing the RNAi drug olpasiran to reduce production of a fatty particle called lipoprotein(a) that is made by a gene at higher levels in about 20% of people. Researchers raced to develop drugs targeting Lp(a) after realizing it contributes to cardiovascular disease.
“There was this ‘Aha’ moment: ‘Oh my gosh, it looks like the higher the Lp(a) level is, based on the genetics of the individual, the more predisposed they are to having these cardiovascular events,’ ” said Narimon Honarpour, Amgen’s vice president of global development.
The drug recently produced promising results in a midstage study, reducing Lp(a) levels by up to 90% or more after 36 and 48 weeks of treatment, Amgen said.
Write to Jared S. Hopkins at jared.hopkins@wsj.com
And Amarin hired a marketing guy to steer the company out of the ditch.
Didn’t Amarin originally think 15% would be the end result?
I wonder how many of the 16 these dopes hounded before they finally snookered two into nodding to their leading questions. Journalists suck!